Novo Nordisk Shares See Further Drop; 'Study Links Ozempic To Higher Risk Of Eye Condition That Can Cause Vision Loss' - STAT News
Novo Nordisk Shares See Further Drop; 'Study Links Ozempic To Higher Risk Of Eye Condition That Can Cause Vision Loss' - STAT News
諾和諾德股價進一步下跌；“研究顯示奧塞米克與一種可能導致視力損失的眼部控件風險更高”的資訊
A new observational study on Wednesday reported for the first time a potential link between Novo Nordisk's GLP-1 drugs Ozempic and Wegovy and an eye condition that can cause vision loss.
週三的一項新的觀察性研究首次報告了諾和諾德的 GLP-1 藥物Ozempic和Wegovy與可能導致視力喪失的眼部疾病之間的潛在聯繫。
After hearing anecdotes of patients on the diabetes and obesity drugs experiencing nonarteritic anterior ischemic optic neuropathy, or NAION, researchers at Massachusetts Eye and Ear analyzed data from a registry of patients at their institution to see if there was a broad trend.
在聽取了服用糖尿病和肥胖藥物的患者出現非動脈炎性前部缺血性視神經病變（NAION）的軼事後，麻省眼耳部的研究人員分析了來自該機構患者登記處的數據，以了解是否有廣泛的趨勢。
Among 710 patients with type 2 diabetes, there were 17 cases of NAION in patients prescribed semaglutide (the scientific name of both drugs). This translated to a cumulative...
在710名2型糖尿病患者中，處方索馬魯肽（兩種藥物...
登入免費觀看全文
登入/註冊